Influence of neurexin 1 (NRXN1) polymorphisms in clozapine response
Corresponding Author
Renan P. Souza
Neurogenetics Section, Neuroscience Department, Centre for Addiction and Mental Health, Toronto, Ontario, Canada
Department of Psychiatry, University of Toronto, Toronto, Ontario, Canada
Centre for Addiction and Mental Health, 250 College St R30, Toronto, ON, Canada.Search for more papers by this authorHerbert Y. Meltzer
Department of Psychiatry, Vanderbilt University, Nashville, Tennessee, USA
Search for more papers by this authorJeffrey A. Lieberman
New York State Psychiatric Institute, Columbia University Medical Centre, New York City, New York, USA
Search for more papers by this authorBernard Le Foll
Translational Addiction Research Laboratory, Centre for Addiction and Mental Health, Toronto, Ontario, Canada
Search for more papers by this authorJames L. Kennedy
Neurogenetics Section, Neuroscience Department, Centre for Addiction and Mental Health, Toronto, Ontario, Canada
Department of Psychiatry, University of Toronto, Toronto, Ontario, Canada
Search for more papers by this authorCorresponding Author
Renan P. Souza
Neurogenetics Section, Neuroscience Department, Centre for Addiction and Mental Health, Toronto, Ontario, Canada
Department of Psychiatry, University of Toronto, Toronto, Ontario, Canada
Centre for Addiction and Mental Health, 250 College St R30, Toronto, ON, Canada.Search for more papers by this authorHerbert Y. Meltzer
Department of Psychiatry, Vanderbilt University, Nashville, Tennessee, USA
Search for more papers by this authorJeffrey A. Lieberman
New York State Psychiatric Institute, Columbia University Medical Centre, New York City, New York, USA
Search for more papers by this authorBernard Le Foll
Translational Addiction Research Laboratory, Centre for Addiction and Mental Health, Toronto, Ontario, Canada
Search for more papers by this authorJames L. Kennedy
Neurogenetics Section, Neuroscience Department, Centre for Addiction and Mental Health, Toronto, Ontario, Canada
Department of Psychiatry, University of Toronto, Toronto, Ontario, Canada
Search for more papers by this authorAbstract
Schizophrenia patients show alterations in the synaptic connectivity. However, it remains unknown whether antipsychotic response may be altered depending on the synaptic connectivity. We tested this association using polymorphisms in the neurexin 1 gene (NRXN1). Large NRXN1 deletions have also been associated with schizophrenia. We genotyped four variants in 140 schizophrenia patients assessed prospectively for clozapine response after 6 months. We observed a trend toward association of clozapine response with the rs12467557 (permuted p = 0.051). These results should be read with caution before independent replication. Copyright © 2010 John Wiley & Sons, Ltd.
REFERENCES
- Bierut LJ, Madden PA, Breslau N, et al. 2007. Novel genes identified in a high-density genome wide association study for nicotine dependence. Hum Mol Genet 16: 24–35.
- Critchlow HM, Maycox PR, Skepper JN, Krylova O. 2006. Clozapine and haloperidol differentially regulate dendritic spine formation and synaptogenesis in rat hippocampal neurons. Mol Cell Neurosci 32: 356–365.
- Dean C, Dresbach T. 2006. Neuroligins and neurexins: linking cell adhesion, synapse formation and cognitive function. Trends Neurosci 29: 21–29.
- Kane J, Honigfeld G, Singer J, Meltzer H. 1988. Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine. Arch Gen Psychiatry 45: 789–796.
- Kattenstroth G, Tantalaki E, Sudhof TC, Gottmann K, Missler M. 2004. Postsynaptic N-methyl-D-aspartate receptor function requires alpha-neurexins. Proc Natl Acad Sci USA 101: 2607–2612.
- Kirov G, Gumus D, Chen W, et al. 2008. Comparative genome hybridization suggests a role for NRXN1 and APBA2 in schizophrenia. Hum Mol Genet 17: 458–465.
- Kirov G, Rujescu D, Ingason A, Collier DA, O'Donovan MC, Owen MJ. 2009. Neurexin 1 (NRXN1) deletions in schizophrenia. Schizophr Bull 35: 851–854.
- Novak G, Boukhadra J, Shaikh SA, Kennedy JL, Le Foll B. 2009. Association of a polymorphism in the NRXN3 gene with the degree of smoking in schizophrenia: a preliminary study. World J Biol Psychiatry 10: 929–935.
- Nussbaum J, Xu Q, Payne TJ, et al. 2008. Significant association of the neurexin-1 gene (NRXN1) with nicotine dependence in European- and African-American smokers. Hum Mol Genet 17: 1569–1577.
- Souza RP, de Luca V, Meltzer HY, Lieberman JA, Kennedy JL. 2010a. Influence of serotonin 3A and 3B receptor genes on clozapine treatment response in schizophrenia. Pharmacogenet Genomics 20: 274–276.
- Souza RP, de Luca V, Meltzer HY, Lieberman JA, Kennedy JL. 2010b. Schizophrenia severity and clozapine treatment outcome association with oxytocinergic genes. Int J Neuropsychopharmacol 13: 793–798.
- Souza RP, Romano-Silva MA, Lieberman JA, et al. 2010c. Genetic association of the GDNF alpha-receptor genes with schizophrenia and clozapine response. J Psychiatr Res 44: 700–706.
- Souza RP, Romano-Silva MA, Lieberman JA, Meltzer HY, Wong AH, Kennedy JL. 2008. Association study of GSK3 gene polymorphisms with schizophrenia and clozapine response. Psychopharmacology (Berl) 200: 177–186.
- Stephan KE, Friston KJ, Frith CD. 2009. Dysconnection in schizophrenia: from abnormal synaptic plasticity to failures of self-monitoring. Schizophr Bull 35: 509–527.
- Sudhof TC. 2008. Neuroligins and neurexins link synaptic function to cognitive disease. Nature 455: 903–911.
- Tabuchi K, Sudhof TC. 2002. Structure and evolution of neurexin genes: insight into the mechanism of alternative splicing. Genomics 79: 849–859.
- Zhang JP, Lencz T, Malhotra AK. 2010. D2 receptor genetic variation and clinical response to antipsychotic drug treatment: a meta-analysis. Am J Psychiatry 167: 763–772.
